Get startedLog in
    Picture of Glenmark Pharmaceuticals logo

    GLENMARK — Glenmark Pharmaceuticals Cashflow Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareBalancedLarge CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    IAS
    IAS
    IAS
    IAS    		—
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line13,82514,4128,6855,69213,992
    Depreciation
    Non-Cash Items2,0133,0048,6073,7904,960
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-8,961-11,197-17,144-20,362-32,088
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Other Operating Cash Flow
    Cash from Operating Activities11,31211,0876,261-4,572-8,276
    Capital Expenditures-7,748-7,901-6,078-9,149-7,507
    Purchase of Fixed Assets
    Other Investing Cash Flow Items9954,56879354,7587,528
    Sale of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Other Investing Cash Flow
    Cash from Investing Activities-6,752-3,333-5,28545,60920.9
    Financing Cash Flow Items-2,936-3,079-4,643-5,168-2,208
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-4,418-5,205-775-39,0617,870
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash2782,7243252,152174